Overview Investigator's Initiated Phase II Study for Pancreatic Cancer Patients Status: Unknown status Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the efficacy, safety and tolerability of TL-118 alone or in combination with pancreatic cancer chemotherapy. Phase: Phase 2 Details Lead Sponsor: Tiltan Pharma Ltd.